Company news

NRX Pharmaceuticals, Inc. news in 2026

NRX Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

NRx Pharmaceuticals (Nasdaq: NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

October 30, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

October 29, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

October 19, 2026

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

October 15, 2026

NRx Defense Systems, an NRx Company (Nasdaq: NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

September 30, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

September 15, 2026

GeNeuro, Inc., an NRx Company (Nasdaq: NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

September 14, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

September 8, 2026

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

August 7, 2026

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

June 25, 2026

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

June 21, 2026

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters Option

June 5, 2026

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

June 4, 2026

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

June 3, 2026

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

June 2, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

May 28, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

May 26, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

May 14, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

May 7, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

May 5, 2026

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

April 21, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

April 20, 2026

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

April 14, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

April 12, 2026

NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

April 7, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

April 5, 2026

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq: NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

March 29, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

March 23, 2026

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

March 18, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application

March 16, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

March 15, 2026

HOPE Therapeutics, an NRx Subsidiary (Nasdaq: NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

March 8, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

March 1, 2026

NRx Builds Momentum From FDA Progress To Strategic Expansion

February 26, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

February 16, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces 2025 Annual Meeting Date and Record Date

January 16, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

January 14, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

January 4, 2026

Calls in 2026

Decks in 2026